EUVIMEDEUVIMED entdecken
Leserbrief

Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab

Qinglin Li, Zulei Shao, Xiaoling Xu iD, Weimin Mao

Journal of Clinical Oncology · 10.11.2026 · 44 (32) · 3174-3175

DOI: 10.1200/jco-26-00565 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2026. Verfasst von Qinglin Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Qinglin Li, MD, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University (Tongde Hospital of Zhejiang Province), Hangzh…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Qinglin Li, MD, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University (Tongde Hospital of Zhejiang Province), Hangzhou, China; Zulei Shao, MM, Postgraduate Training Base Alliance, Wenzho…

ORCID-Profile: Xiaoling Xu

Zitieren

APA

Li, Q., Shao, Z., Xu, X., & Mao, W. (2026). Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab. Journal of Clinical Oncology, 44(32), 3174-3175. https://doi.org/10.1200/jco-26-00565

Vancouver

Li Q, Shao Z, Xu X, Mao W. Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab. Journal of Clinical Oncology. 2026;44(32):3174-3175. doi:10.1200/jco-26-00565

BibTeX
@article{Li2026,
  author = {Li, Qinglin and Shao, Zulei and Xu, Xiaoling and Mao, Weimin},
  title = {Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {32},
  pages = {3174--3175},
  doi = {10.1200/jco-26-00565}
}
Kostenlos starten →